Literature DB >> 32690970

Glycosylase base editors enable C-to-A and C-to-G base changes.

Dongdong Zhao1, Ju Li2, Siwei Li1, Xiuqing Xin1,3, Muzi Hu1,4, Marcus A Price5, Susan J Rosser5, Changhao Bi6, Xueli Zhang7.   

Abstract

Current base editors (BEs) catalyze only base transitions (C to T and A to G) and cannot produce base transversions. Here we present BEs that cause C-to-A transversions in Escherichia coli and C-to-G transversions in mammalian cells. These glycosylase base editors (GBEs) consist of a Cas9 nickase, a cytidine deaminase and a uracil-DNA glycosylase (Ung). Ung excises the U base created by the deaminase, forming an apurinic/apyrimidinic (AP) site that initiates the DNA repair process. In E. coli, we used activation-induced cytidine deaminase (AID) to construct AID-nCas9-Ung and found that it converts C to A with an average editing specificity of 93.8% ± 4.8% and editing efficiency of 87.2% ± 6.9%. For use in mammalian cells, we replaced AID with rat APOBEC1 (APOBEC-nCas9-Ung). We tested APOBEC-nCas9-Ung at 30 endogenous sites, and we observed C-to-G conversions with a high editing specificity at the sixth position of the protospacer between 29.7% and 92.2% and an editing efficiency between 5.3% and 53.0%. APOBEC-nCas9-Ung supplements the current adenine and cytidine BEs (ABE and CBE, respectively) and could be used to target G/C disease-causing mutations.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32690970     DOI: 10.1038/s41587-020-0592-2

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  60 in total

1.  Attaining the promise of plant gene editing at scale.

Authors:  Ryan A Nasti; Daniel F Voytas
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-30       Impact factor: 11.205

Review 2.  CRISPR in cancer biology and therapy.

Authors:  Alyna Katti; Bianca J Diaz; Christina M Caragine; Neville E Sanjana; Lukas E Dow
Journal:  Nat Rev Cancer       Date:  2022-02-22       Impact factor: 60.716

Review 3.  State-of-the-art CRISPR for in vivo and cell-based studies in Drosophila.

Authors:  Jonathan Zirin; Justin Bosch; Raghuvir Viswanatha; Stephanie E Mohr; Norbert Perrimon
Journal:  Trends Genet       Date:  2021-12-18       Impact factor: 11.639

4.  Efficient C•G-to-G•C base editors developed using CRISPRi screens, target-library analysis, and machine learning.

Authors:  Luke W Koblan; Mandana Arbab; Max W Shen; Jeffrey A Hussmann; Andrew V Anzalone; Jordan L Doman; Gregory A Newby; Dian Yang; Beverly Mok; Joseph M Replogle; Albert Xu; Tyler A Sisley; Jonathan S Weissman; Britt Adamson; David R Liu
Journal:  Nat Biotechnol       Date:  2021-06-28       Impact factor: 54.908

Review 5.  Recent advances in CRISPR technologies for genome editing.

Authors:  Myeonghoon Song; Taeyoung Koo
Journal:  Arch Pharm Res       Date:  2021-06-23       Impact factor: 4.946

Review 6.  Single-Base Resolution: Increasing the Specificity of the CRISPR-Cas System in Gene Editing.

Authors:  Roy Rabinowitz; Daniel Offen
Journal:  Mol Ther       Date:  2020-11-26       Impact factor: 11.454

Review 7.  On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis.

Authors:  Marjolein Ensinck; Angélique Mottais; Claire Detry; Teresinha Leal; Marianne S Carlon
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

Review 8.  CRISPR-based genome editing through the lens of DNA repair.

Authors:  Tarun S Nambiar; Lou Baudrier; Pierre Billon; Alberto Ciccia
Journal:  Mol Cell       Date:  2022-01-20       Impact factor: 17.970

9.  Highly Efficient CRISPR-Mediated Base Editing in Sinorhizobium meliloti.

Authors:  Longxiang Wang; Yuan Xiao; Xiaowei Wei; Jimin Pan; Deqiang Duanmu
Journal:  Front Microbiol       Date:  2021-06-18       Impact factor: 5.640

10.  Versatile and efficient in vivo genome editing with compact Streptococcus pasteurianus Cas9.

Authors:  Zhiquan Liu; Siyu Chen; Wanhua Xie; Yuning Song; Jinze Li; Liangxue Lai; Zhanjun Li
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.